Abstract
Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.
Publication types
-
Clinical Trial, Phase IV
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Benzoxazines / administration & dosage
-
Benzoxazines / adverse effects
-
Cholesterol, LDL / blood*
-
Cholesterol, LDL / drug effects
-
Coronary Disease / chemically induced
-
Coronary Disease / prevention & control
-
Cross-Over Studies
-
Cyclopropanes
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Dyslipidemias / blood
-
Dyslipidemias / chemically induced
-
Dyslipidemias / prevention & control*
-
Female
-
Follow-Up Studies
-
HIV Infections / diagnosis
-
HIV Infections / drug therapy*
-
Humans
-
Male
-
Nevirapine / administration & dosage*
-
Nevirapine / adverse effects
-
Reverse Transcriptase Inhibitors / administration & dosage*
-
Reverse Transcriptase Inhibitors / adverse effects
-
Severity of Illness Index
-
Single-Blind Method
-
Treatment Outcome
Substances
-
Alkynes
-
Benzoxazines
-
Cholesterol, LDL
-
Cyclopropanes
-
Reverse Transcriptase Inhibitors
-
Nevirapine
-
efavirenz